MARKET

ALPN

ALPN

Alpine Immune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.480
+0.080
+3.33%
Closed 16:00 03/27 EDT
OPEN
2.410
PREV CLOSE
2.400
HIGH
2.600
LOW
2.410
VOLUME
12.73K
TURNOVER
--
52 WEEK HIGH
8.24
52 WEEK LOW
2.050
MARKET CAP
46.10M
P/E (TTM)
-0.8986
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALPN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALPN stock price target is 12.75 with a high estimate of 17.00 and a low estimate of 8.00.

EPS

ALPN News

More
  • Alpine Immune Sciences up 7% on Orphan Drug tags for lead drug
  • Seeking Alpha - Article · 03/18 13:31
  • Alpine Immune Sciences ALPN-101 Receives FDA Orphan Drug Designations for the Prevention and Treatment of Acute Graft Versus Host Disease
  • Business Wire · 03/18 12:15
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36
  • Alpine Immune Sciences' ALPN-101 Receives FDA Orphan Drug Designations For Prevention And Treatment Of Acute Graft Versus Host Disease
  • Benzinga · 03/18 11:17

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About ALPN

Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.
More

Webull offers kinds of Alpine Immune Sciences Inc stock information, including NASDAQ:ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions.